ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / XBIO / options
CANF (25) AZTR (33) APUS (37) TRAW (31) ⌘ Pro Terminal β†’

Xenetic Biosciences Inc. (XBIO) Options Positioning, Max Pain & Unusual Sweeps

$2.06 +0.49% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.06

Xenetic Biosciences Inc. (XBIO) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $4.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XBIO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is XBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Xenetic Biosciences Inc. (NASDAQ: XBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.06 (+0.49% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XBIO ranks #743 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does XBIO compare to CANF and AZTR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIO carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -30.3%. By comparison, CANF (Can-Fite Biopharma Ltd each representing two (2)) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $4.9M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, XBIO leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XBIO?
β–Ό

Per XBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534525), Xenetic Biosciences Inc. generated $3.0M in revenue (+19.0% YoY), -$2.7M in net income, and -$2.3M in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.06 (-0.10%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (6)Whales (3)SEC (11)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$5 Bull$2 Base$1 Bear
πŸ“¬ FREE XBIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for XBIO)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY XBIO SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime Γ— Technicals: 14% of 52W Range β€’ RSI-14 at 44 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$2.10-4.8% Next Q
Q2 (-2Q)
37
Grade E$2.00-8.5% Next Q
Q3 (-1Q)
35
Grade E$1.83+12.6% Next Q
Current
32
Grade E$2.06-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a XBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While XBIO currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.78) and Max Pain ($2.16) forces dealer call-delta covering toward $5.19.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XBIOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œXBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (XBIO)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for XBIO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XBIO)

  • βœ“Walkthrough of XBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
XBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.41%πŸ“ HORIZONTAL RANGE
2026-11-03O $2.12H $2.12L $2.05C $2.06VOL 32.6K
RES: $5.77SUP: $1.52SMA50: $2.78SMA200: $2.84
$5.18$4.20$3.23$2.25$1.28RES $5.77SUP $1.52$2.062026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ XBIO Butterfly Map β†’ + Track XBIO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XBIO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for XBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XBIO)

Health Care Rank #743 of 1015 βš”οΈ CANF vs XBIO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (XBIO vs. CANF, AZTR, APUS, TRAW)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Xenetic Biosciences Inc. (XBIO) ranks #743 by composite RQD confidence (32/100, grade E) and #948 by equity capitalization ($4.8M). Within this direct 5-issuer industry benchmark cohort, XBIO leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and β€” gross margin. APUS currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with XBIO at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XBIO ACTIVE
Xenetic Biosciences Inc.
E 32/100 β€” β€” -30.3% +0.49% $4.8M Benchmark Subject
CANF
Can-Fite Biopharma Ltd each representing two (2)
E 25/100 β€” β€” -35.0% +0.62% $4.9M /canf-vs-xbio β†’
AZTR
Azitra Inc
E 33/100 β€” β€” -35.0% +8.72% $4.7M /aztr-vs-xbio β†’
APUS
Apimeds Pharmaceuticals US Inc.
D- 37/100 β€” β€” -6.2% -3.99% $4.6M /apus-vs-xbio β†’
TRAW
Traws Pharma Inc.
E 31/100 β€” β€” -35.0% +1.45% $4.5M /traw-vs-xbio β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001534525 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xenetic Biosciences Inc. (XBIO) reported GAAP revenue of $3.0M (+19.0% vs. FY2024 revenue of $2.5M , and +17.2% cumulative change since FY2023) , GAAP net income of -$2.7M, operating cash flow of -$2.3M, and free cash flow of -$2.3M (+18.8% YoY). On the balance sheet, XBIO closed FY2025 with $8.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.0M -$2.7M -$2.3M -$2.3M $8.4M β€”
FY2024 (FY) 2024-12-31 $2.5M -$4.0M -$2.8M -$2.8M $6.9M β€”
FY2023 (FY) 2023-12-31 $2.5M -$4.1M -$4.1M -$4.1M β€” β€”

3. XBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Xenetic Biosciences Inc. (NASDAQ: XBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.06 (+0.49% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XBIO ranks #743 in composite RQD confidence.

How does XBIO compare to CANF and AZTR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIO carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -30.3%. By comparison, CANF (Can-Fite Biopharma Ltd each representing two (2)) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $4.9M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, XBIO leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XBIO?

Per XBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534525), Xenetic Biosciences Inc. generated $3.0M in revenue (+19.0% YoY), -$2.7M in net income, and -$2.3M in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

XBIO last traded at $2.06 (+0.49% on volume of 29,702 shares), positioning the stock -25.90% below its 50-day simple moving average ($2.78) and -27.46% below its 200-day simple moving average ($2.84). Across its 52-week range of $1.58 to $4.94, XBIO sits at the 14.3% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.80 to $2.32).

Direct Sub-Reports: XBIO RQD Cockpit XBIO 12M Forecast XBIO Earnings & Move XBIO Dividends & DRIP XBIO Insiders & 13F XBIO Whale Options XBIO Profit Sankey XBIO News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

XBIO β€” Xenetic Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Xenetic Biosciences Inc. (XBIO) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.06 (+0.49% 1D, market capitalization $4.8M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -30.3%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Xenetic Biosciences Inc. (XBIO) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xenetic Biosciences Inc. (XBIO) reported $3.0M in annual revenue (up from $2.5M in FY2024, +19.0% YoY) and -$2.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, -$4.1M net income) through FY2025, XBIO scaled operating cash flow to -$2.3M and free cash flow to -$2.3M, backed by $8.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.58 – $4.94 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order bottleneck links are recorded.

  • Key Question #1: Can XBIO sustain or expand its -60.0% operating margin and -30.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.0M and free cash flow of -$2.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is XBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xenetic Biosciences Inc. (XBIO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to XBIO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XBIO Bull vs. Bear Conversation Board β€” What's Your Call at $2.06?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XBIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XBIO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $2.62 (+27.8%)
πŸ“Œ Pinned Debate

The company has a live clinical-stage catalyst, a first patient dosed in an investigator-initiated lymphoma study, that could re-rate a

Picked up a starter position in XBIO in my $100K Virtual Cash book at $2.05. The company has a live clinical-stage catalyst, a first patient dosed in an investigator-initiated lymphoma study, that could re-rate a stock trading at a $5.0M market cap.. Trading inside a $1.58–$4.94 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” XBIO's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.74 (-15.1%)
Spot @ $2.05

Operating losses have run every year from FY 2023 to FY 2025, with ROIC at -30.3% and FCF yield at 0%, against a Strong Sell RQD score

Operating losses have run every year from FY 2023 to FY 2025, with ROIC at -30.3% and FCF yield at 0%, against a Strong Sell RQD score of 34.. Look at the math on XBIO: paying current EV/EBITDA multiples for -30.3% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.80 before getting long.

LIVE TAPE